| [1] |
American Thyroid Association(ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2009, 19(11): 1167-1214. doi: 10.1089/thy.2009.0110 |
| [2] |
张桂芝, 谭建, 刘雪辉, 等. 131I治疗分化型甲状腺癌术后患者疗效影响因素研究[J].中华核医学杂志, 2010, 30(4): 259-263. doi: 10.3760/cma.j.issn.0253-9780.2010.04.011 |
| [3] |
张洁, 石洪成.分化型甲状腺癌131I治疗的现状[J].国际放射医学核医学杂志, 2009, 33(3): 163-167. doi: 10.3760/cma.j.issn.1673-4114.2009.03.009 |
| [4] |
中华医学会内分泌学分会, 中华医学会外科学分会内分泌学组, 中国抗癌协会头颈肿瘤专业委员会, 等.甲状腺结节和分化型甲状腺癌诊治指南[J].中华核医学与分子影像杂志, 2013, 33(2): 96-115. doi: 10.3760/cma.j.issn.2095-2848.2013.02.003 |
| [5] |
匡安仁. 131I治疗分化型甲状腺癌[M]. 1版.北京:人民卫生出版社, 2013: 102-103. |
| [6] |
刘斌, 王建涛, 牟达, 等. 131I治疗分化型甲状腺癌血液和骨髓的吸收剂量及剂量学导向治疗法[J].中华核医学杂志, 2010, 30(2): 142-144. doi: 10.3760/cma.j.issn.0253-9780.2010.02.024 |
| [7] |
Lassmann M, Hänscheid H, Chiesa C, et al. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy[J]. Eur J Nucl Med Mol Imaging, 2008, 35(7): 1405-1412. doi: 10.1007/s00259-008-0761-x |
| [8] |
Sieqel JA. Revised Nuclear Regulatory Commission regulations for release of patients administered radioactive materials: outpatient iodine-131 anti-B1 therapy[J]. J Nucl Med, 1998, 39(8 Suppl): S28-33. |
| [9] |
中华人民共和国卫生部. GBZ120-2006临床核医学放射卫生防护标准[S].北京: 人民卫生出版社, 2006. |